

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

September 29 2012

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

[Sorafenib](#) is an oral inhibitor of several tyrosine protein kinases, which can be active in cancers. At the meeting, Dr Luis Paz-Ares from from Virgen del Rocio University Hospital in Seville, Spain, reported the findings of the phase III MISSION trial, a randomized, double-blind, placebo-controlled study of monotherapy administration of sorafenib in 703 patients who were randomly assigned to either oral sorafenib 400mg twice daily or placebo.

Median overall survival, the study's primary end-point, was similar in the two groups (248 vs 253 days; HR 0.99, $p=0.4687$) the researchers found, while median progression-free survival (HR 0.61; p

Citation: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer (2012, September 29) retrieved 20 April 2024 from <https://medicalxpress.com/news/2012-09-sorafenib-survival-fourth-line-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.